Abstract
ObjectivesPevonedistat is a new cytotoxic used in association with azacitidine for the treatment of acute myeloid leukaemia and high-risk myelodysplastic syndromes. The manufacturer indicates an 18-hour stability after dilution in...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have